Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 732 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Carbohydrate 50% Clear all
Not listed Phase 2 Interventional

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

NCT03570983
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Allopurinol, Carmustine, Etoposide, Cytarabine, Melphalan
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 15, 2026, 10:52 AM EDT
Completed Phase 2 Interventional Results available

Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors

NCT00061893
View directory record Official record
Conditions
Sarcoma
Interventions
celecoxib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vinblastine sulfate, vincristine sulfate, conventional surgery, radiation therapy, MESNA, Filgrastim
Drug · Procedure · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 50 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
87
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 15, 2026, 10:52 AM EDT
Completed Phase 2 Interventional Results available

Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma

NCT00866749
View directory record Official record
Conditions
Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions
Daunorubicin, Vincristine, PEG-asparaginase, Intrathecal Methotrexate, Cyclophosphamide, Cytarabine, Mercaptopurine, Methotrexate, Doxorubicin, Thioguanine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 15, 2026, 10:52 AM EDT
Recruiting Not applicable Interventional

Symptoms of Polycystic Ovarian Syndrome Ameliorated by Keto-Adaptation Pilot

NCT07227363
View directory record Official record
Conditions
PCOS (Polycystic Ovary Syndrome)
Interventions
Ketogenic diet, Exogenous Ketone Supplement
Other · Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 15, 2026, 10:52 AM EDT
Completed Not applicable Interventional Results available

Optimizing Individual Nutrition in Preterm Very Low Birth Weight Infants

NCT02372136
View directory record Official record
Conditions
Infant, Premature, Diseases, Infant, Small for Gestational Age
Interventions
Individualized Nutrition, Optimized nutrition
Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 7 Days
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 15, 2026, 10:52 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer

NCT04243616
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
Cemiplimab, Paclitaxel, Carboplatin (not mandatory), Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 15, 2026, 10:52 AM EDT
Terminated Phase 1 Interventional Results available

EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

NCT01186328
View directory record Official record
Conditions
Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, T Cell, Leukemia, Lymphoblastic, Acute
Interventions
EZN-3042, Cytarabine, Doxorubicin, Prednisone, Vincristine, PEG-asparaginase, Methotrexate, Hydrocortisone
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 15, 2026, 10:52 AM EDT
Recruiting Phase 2 Interventional

Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis

NCT03835767
View directory record Official record
Conditions
Milk and/or Peanut Allergy
Interventions
Peanut powder and Oat flour, Peanut flour and Oat flour (placebo for peanut flour), Dry Milk Powder and Corn Starch (placebo for Milk powder), Baked milk and Rice milk (placebo for Baked milk)
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 21 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 15, 2026, 10:52 AM EDT
Completed Phase 4 Interventional Results available

Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder

NCT00536198
View directory record Official record
Conditions
Premenstrual Dysphoric Disorder
Interventions
Sertraline, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 48 Years · Female only
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
New Haven, Connecticut • New York, New York • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 15, 2026, 10:52 AM EDT
Terminated Not applicable Interventional Results available

Stimulant Enhancement of Well-Being Therapy for Depression

NCT01478113
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Amphetamine/dextroamphetamine, Placebo, Well-being therapy
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 15, 2026, 10:52 AM EDT
Completed Phase 4 Interventional Results available

Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa

NCT02513485
View directory record Official record
Conditions
Depression
Interventions
Levodopa+carbidopa, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 19, 2022 · Synced Oct 15, 2026, 10:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Young Adult Eating Habits

NCT05550818
View directory record Official record
Conditions
Eating Behavior, Eating Habit
Interventions
High Ultra Processed Food Diet, No Ultra Processed Food Diet
Other
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
18 Years to 25 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Blacksburg, Virginia • Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 15, 2026, 10:52 AM EDT
Recruiting Not applicable Interventional

Well-Formulated Ketogenic Diet Polycystic Kidney Disease

NCT06325644
View directory record Official record
Conditions
Polycystic Kidney Disease
Interventions
Ketogenic Diet, Ketone/Glucose Monitoring, CGM/CKM, Blood Draw, Body Composition, Change in glomerular filtration rate (mg/mmol) via magnetic resonance imaging (MRI) .
Other · Biological
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 15, 2026, 10:52 AM EDT
Completed Phase 4 Interventional Results available

D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions

NCT01981759
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Delusional Disorder
Interventions
D-Cycloserine, Placebo, Cognitive Behavioral Therapy
Drug · Other · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 68 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 15, 2026, 10:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Postprandial Hyperglycemia on Vasculature in Type 1 Diabetes and Healthy Adults

NCT04730882
View directory record Official record
Conditions
Type 1 Diabetes, Hyperglycemia, Postprandial
Interventions
Mixed Meal
Dietary Supplement
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 35 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 15, 2026, 10:52 AM EDT
Completed Phase 2Phase 3 Interventional

Low Glycemic Load Diets in Latino Children at Risk for Type 2 Diabetes

NCT01068197
View directory record Official record
Conditions
Obesity, Type 2 Diabetes Mellitus
Interventions
Low Glycemic Load Diet versus Low Fat Diet
Behavioral
Lead sponsor
Nazrat Mirza
Other
Eligibility
7 Years to 14 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 15, 2026, 10:52 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Influence of Obesity on Endogenous Oxalate Synthesis

NCT03704350
View directory record Official record
Conditions
Kidney Stone
Interventions
controlled diet
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 15, 2026, 10:52 AM EDT
Completed Phase 3 Interventional Results available

DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation

NCT00083915
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cisplatin, Cyclophosphamide, Adriamycin, Etoposide, Melphalan, Thalidomide, Dexamethasone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 15, 2026, 10:52 AM EDT
Completed Phase 2 Interventional

Predicting Weight Gain and Weight Loss Associated With Overeating or Fasting

NCT00687115
View directory record Official record
Conditions
Obesity, Diet Therapy, Weight Loss, Weight Gain, Nutrition Therapy
Interventions
Weight Loss, Overfeeding, Overfeeding Low Pro
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 60 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 15, 2026, 10:52 AM EDT
Completed Not applicable Interventional

Urinary Tract Infections Rates Using 50% Dextrose Plus Washout Versus Normal Saline as Cystoscopy Fluid

NCT03719755
View directory record Official record
Conditions
Hysterectomy
Interventions
50% dextrose, Normal Saline
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 15, 2026, 10:52 AM EDT
Completed Phase 4 Interventional Results available

Acute Psychotherapy for Bipolar II Depression

NCT01133821
View directory record Official record
Conditions
Bipolar Disorder, Depression
Interventions
IPSRT plus placebo (IPSRT-PLA), IPSRT plus quetiapine
Drug
Lead sponsor
Holly Swartz
Other
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 15, 2026, 10:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

NCT02464657
View directory record Official record
Conditions
Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Nivolumab, Idarubicin, Cytarabine, Solu-medrol, Dexamethasone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 15, 2026, 10:52 AM EDT
Completed Phase 1 Interventional

Development of Ibudilast for Alcohol Use Disorder

NCT02025998
View directory record Official record
Conditions
Alcohol Use Disorders
Interventions
Ibudilast, Matched placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 15, 2026, 10:52 AM EDT
Not listed Phase 2 Interventional

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

NCT01903330
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
ERC1671, GM-CSF, Cyclophosphamide, Oral Control (Sucrose pill), Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%)), Bevacizumab/Bevacizumab Biosimilar
Drug
Lead sponsor
Epitopoietic Research Corporation
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
3
States / cities
Orange, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 15, 2026, 10:52 AM EDT